Hemophilia A With Inhibitor Clinical Trial
Official title:
An Exploratory Study to Evaluate the Dose Response-Relationship of Pharmacodynamic Parameters of AryoSeven, in Patients With Hemophilia With Inhibitors
Randomized, double-blind, single-dose, 5 ways crossover, exploratory clinical trial evaluating four different doses of AryoSeven (eptacog alfa, activated) and NovoSeven on selected pharmacodynamic parameters in patients with hemophilia with inhibitors.
Randomized, double-blind, single dose, 5 ways crossover, clinical trial evaluating four different doses (10 µg/kg, 30 µg/kg, 90 µg/kg, and 270 µg/kg) of AryoSeven (recombinant human FVII activated or eptacog alfa, activated) and one dose of NovoSeven (30 µg/kg) on selected pharmacodynamic parameters (PD) [Primary: Thrombin Generation Assay (TGA)] in male adult and adolescent (>12 years) patients with hemophilia A or B, with an inhibitors titer >5 Bethesda Units [BU] and not in bleeding status. This will be an exploratory study to evaluate dose-response relationship of PD markers as surrogate efficacy endpoints. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06320626 -
Pharmacokinetic-guided Dosing of Emicizumab
|
Phase 4 | |
Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
Not yet recruiting |
NCT02554526 -
Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors
|
N/A | |
Completed |
NCT03818529 -
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
|
||
Active, not recruiting |
NCT03619863 -
ATHN 7: Hemophilia Natural History Study
|
||
Recruiting |
NCT06010953 -
SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT03951103 -
rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A
|
||
Recruiting |
NCT05888870 -
ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor
|
Phase 4 | |
Terminated |
NCT04303572 -
The Hemophilia Inhibitor Eradication Trial
|
Phase 3 | |
Terminated |
NCT04489537 -
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B
|
Phase 3 | |
Terminated |
NCT04548791 -
Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT06357572 -
Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem
|
||
Recruiting |
NCT04647227 -
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
|
Phase 4 | |
Completed |
NCT03372993 -
Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
|
||
Terminated |
NCT03204539 -
INdividualized ITI Based on Fviii(ATE) Protection by VWF
|
Phase 4 | |
Active, not recruiting |
NCT04205175 -
A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab
|
Phase 4 | |
Recruiting |
NCT06312475 -
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
|
Phase 3 | |
Recruiting |
NCT03598725 -
Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China
|
Phase 4 | |
Completed |
NCT04723693 -
An Exploration of the Impact of Emicizumab on the Lives of People With Haemophilia and Inhibitors and Their Families
|
||
Recruiting |
NCT04592692 -
A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip
|
Phase 2 |